Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Joint Venture, Subsidiary

Established: 1997-04-16

Employees: -

Market Cap: -

Website: http://www.cttq.com

Clinical Trials

A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients

Phase 3

Not yet recruiting

Conditions: Small Cell Lung Cancer Limited Stage

Interventions: Drug: TQB2450+Anlotinib
Drug: TQB2450 placebo + Anlotinib placebo

First Posted Date: 2024-06-24

Last Posted Date: 2024-07-01

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 358

Registration Number: NCT06469879

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
AnYang Tumor Hospital, Anyang, Henan, China
🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China

and more 13 locations

A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B

Phase 1

Not yet recruiting

Conditions: Hepatitis B, Chronic

Interventions: Drug: TQA3038 injection/placebo
Drug: Nucleotide drugs Control group

First Posted Date: 2024-06-11

Last Posted Date: 2024-06-11

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 162

Registration Number: NCT06452693

Locations: 🇨🇳
Gansu province people hospital, Lanzhou, Gansu, China
🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China

and more 19 locations

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects

Phase 1

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: TQB3702 tablets
Drug: TQB3702 placebo

First Posted Date: 2024-06-07

Last Posted Date: 2024-08-12

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT06448273

Locations: 🇨🇳
Guangdong provincial people's hospital, Guangzhou, Guangdong, China

Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps

Phase 2

Recruiting

Conditions: Chronic Rhinosinusitis

Interventions: Drug: 300mg/600mg of TQH2722 injection

First Posted Date: 2024-06-03

Last Posted Date: 2024-10-31

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT06439381

Locations: 🇨🇳
Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
The First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳
The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China

and more 24 locations

The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

Phase 3

Not yet recruiting

Conditions: T-lymphoblastic Leukemia
T-lymphoblastic Lymphoma

Interventions: Drug: Nelarabine injection

First Posted Date: 2024-05-30

Last Posted Date: 2024-05-30

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 83

Registration Number: NCT06434467

Locations: 🇨🇳
The first hospital of Lanzhou University, Lanzhou, Gansu, China
🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Aerospace Medical Center, Beijing, Beijing, China

and more 27 locations

Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets

Phase 1

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: TQA3810

First Posted Date: 2024-05-28

Last Posted Date: 2024-05-28

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 759

Registration Number: NCT06431438

Locations: 🇨🇳
Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, Jiangsu, China

A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer

Phase 1

Not yet recruiting

Conditions: Advanced Malignant Cancer

Interventions: Drug: TQB3117 tablets

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-16

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 59

Registration Number: NCT06415903

Locations: 🇨🇳
The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

Phase 1

Recruiting

Conditions: Advanced Cancers

Interventions: Drug: TQB3107 Tablets

First Posted Date: 2024-05-14

Last Posted Date: 2024-07-03

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 140

Registration Number: NCT06413953

Locations: 🇨🇳
Sun Yat-sen University Cancer Cen, Guangzhou, Guangdong, China

A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: TQC3927 powder for inhalation
Drug: TQC3927 powder for inhalation placebo

First Posted Date: 2024-05-10

Last Posted Date: 2024-10-29

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT06408285

Locations: 🇨🇳
China Japan Friendship Hospital, Beijing, Beijing, China

TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients

Phase 1

Active, not recruiting

Conditions: Myelofibrosis

Interventions: Drug: TQ05105 Tablets

First Posted Date: 2024-04-29

Last Posted Date: 2024-04-29

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 9

Registration Number: NCT06388759

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy